Influence of liver cirrhosis on sertraline pharmacokinetics. 1996

J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
Clinical Pharmacology Unit, Saint-Antoine University Hospital, Paris, France.

Sertraline is a serotonin reuptake inhibitor. The enhancement of serotoninergic transmission is associated with antidepressant activity. In order to determine the pharmacokinetics of sertraline in patients with chronic stable hepatic insufficiency, 10 patients were matched (age, weight, sex) with 10 healthy subjects in an open study. Each participant received a single capsule containing the equivalent of 100 mg sertraline base. Blood samples were taken during 264 h after administration for measurement of plasma concentrations of sertraline. The results confirm that the oral clearance of sertraline is reduced with a 1.7-fold increase in Cmax and a significant prolongation in elimination half-life in hepatically impaired patients.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D015057 1-Naphthylamine A suspected industrial carcinogen (and listed as such by OSHA). Its N-hydroxy metabolite is strongly carcinogenic and mutagenic. 1-Aminonaphthalene,alpha-Naphthylamine,8-Aminonaphthalene,Naphthalidine,1 Aminonaphthalene,1 Naphthylamine,8 Aminonaphthalene,alpha Naphthylamine
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin

Related Publications

J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
May 2001, British journal of clinical pharmacology,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
January 1989, International journal of clinical pharmacology research,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
April 2009, Journal of clinical pharmacology,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
January 1977, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
January 1990, Chemotherapy,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
January 1982, Giornale italiano di chemioterapia,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
January 2002, Clinical pharmacokinetics,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
January 1984, European journal of clinical pharmacology,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
July 2013, Vnitrni lekarstvi,
J L Démolis, and P Angebaud, and J D Grangé, and P Coates, and C Funck-Brentano, and P Jaillon
December 1990, Biopharmaceutics & drug disposition,
Copied contents to your clipboard!